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Abstract The use of an appropriate reference gene to
ensure accurate normalisation is crucial for the correct
quantiﬁcation of gene expression using qPCR assays and
RNA arrays. The main criterion for a gene to qualify as a
reference gene is a stable expression across various cell
types and experimental settings. Several reference genes
are commonly in use but more and more evidence reveals
variations in their expression due to the presence of on-
going neuropathological disease processes, raising doubts
concerning their use. We conducted an analysis of genome-
wide changes of gene expression in the human central
nervous system (CNS) covering several neurological dis-
orders and regions, including the spinal cord, and were able
to identify a number of novel stable reference genes. We
tested the stability of expression of eight novel (ATP5E,
AARS, GAPVD1, CSNK2B, XPNPEP1, OSBP, NAT5 and
DCTN2) and four more commonly used (BECN1, GAP-
DH, QARS and TUBB) reference genes in a smaller cohort
using RT-qPCR. The most stable genes out of the 12 ref-
erence genes were tested as normaliser to validate
increased levels of a target gene in CNS disease. We found
that in human post-mortem tissue the novel reference
genes, XPNPEP1 and AARS, were efﬁcient in replicating
microarray target gene expression levels and that XPN-
PEP1 was more efﬁcient as a normaliser than BECN1,
which has been shown to change in expression as a
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DOI 10.1007/s00401-012-1027-zconsequence of neuronal cell loss. We provide herein one
more suitable novel reference gene, XPNPEP1, with no
current neuroinﬂammatory or neurodegenerative associa-
tions that can be used for gene quantitative gene expression
studies with human CNS post-mortem tissue and also
suggest a list of potential other candidates. These data also
emphasise the importance of organ/tissue-speciﬁc stably
expressed genes as reference genes for RNA studies.
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Introduction
Reference or so-called ‘‘housekeeping’’ genes are widely
used as internal standards in mRNA-based techniques such
as reverse transcription quantitative real-time polymerase
chain reaction (RT-qPCR) [9, 31] and microarray tech-
nologies [35]. Current guidelines recommend the use of
reference genes over housekeeping genes to refer to
internal controls [10]. A reference gene is one that is
constitutively expressed in all nucleated cell types, is
involved in basal cell metabolism or survival and is deﬁned
as a gene showing the most stable expression across vari-
ous tissue types and experimental conditions. Quantitative
mRNA studies are commonly conducted to compare
expression levels of a target gene or gene of interest (GOI)
between disease and non-disease and such data need to be
normalised to a reference gene.
It is essential whenconducting such studies to ensure that
all the samples contain the same amount of RNA. Biolog-
ical parameters such as tissue volume, mass, size or cell
number were ﬁrst employed as normalisation procedures
(absolute quantiﬁcation). However, variability in biological
samples rendered this method impractical and unreliable
[8]. When comparing the amount of RNA, it was found that
normalisation with an internal reference gene was more
appropriate (relative or comparative quantiﬁcation), since it
compensates for sample-to-sample variations in total RNA
amount. Relative quantiﬁcation compares changes of
mRNA levels between two genes with one of them being
the endogenous reference (the normaliser) and will deter-
mine the expression of a GOI relative to the reference
gene. The most commonly used reference genes are
GAPDH (glyceraldehyde-3-phosphate dehydrogenase),
HPRT1 (hypoxanthine phosphoribosyltransferase 1), albu-
min, actins, tubulins, cyclophilin, microglobulins, beclin
and ribosomal subunits [48, 49]. Although well established,
data normalisation using an internal reference gene is sub-
ject to frequent criticism since the quality of normalised
expression levels is entirely dependent on the quality of the
normaliser [26]. Any variations in expression of the nor-
maliser will result in obscuring real changes and will
produce artifactual changes [7]. Hence, to carry out
appropriate normalisation in RT-qPCR, suitable reference
genes are vital to the generation of biologically relevant
results [3, 17].
There are increasing concerns about some of the more
conventional reference genes when investigating mRNA
expression levels in the human brain [26]. For example,
GAPDH is mostly known for its role in glycolysis, but
recent reports have demonstrated increased GAPDH
activity associated with cell fate and neurodegeneration
[14, 43]. Furthermore, increased beclin expression has been
associated with neurones and astrocytes at the site of
traumatic brain injury [12]. A similar scenario is emerging
for actin [40]. Some concerns have also been raised when
normalising against 18S ribosomal RNA, which is much
more abundant than other mRNA species and, therefore,
may not be the best to compare with mRNA species of
lower abundance [9, 44]. Moreover, we have demon-
strated that not all mRNAs in the CNS, 18S ribosomal
RNA being one of them, appear to deteriorate in a similar
manner with increasing post-mortem delay based on RIN
assessment [19]. These studies would suggest that the
identiﬁcation of a universal human reference gene might
prove more challenging than initially thought and that,
perhaps, novel organ and tissue-speciﬁc reference genes
might be more appropriate and useful. Indeed, the litera-
ture shows that an ideal and universal reference gene
remains to be discovered [6, 7, 42, 48]. There are very few
investigative reports to date that have been published
trying to establish and validate reference genes for
quantitative gene expression analysis of human CNS post-
mortem tissue [15, 27].
Several studies have been conducted to isolate stably
expressed genes using microarray data. Large scale cate-
gorisation of reference genes based on microarray data has
generated three lists of reference genes widely cited in the
literature, Warrington et al. [51], Hsiao et al. [25], and
Eisenberg et al. [22, 46]. Zhu et al. [54] generated an up-
dated list of reference genes using more advanced arrays
with an increased number of probes. Finally, de Jonge et al.
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123[16] conducted a meta-analysis of 13,629 human gene
array samples and found a selection of candidate genes
showing a stable expression across various human cell
types and experimental conditions. Very few studies to
date have been conducted using qPCR to investigate
stable gene expression in the CNS. Penna et al. [39]f o u n d
t h a tC Y C 1a n dE I F 4 A 2s h o w e ds t a b l ee x p r e s s i o ni n
Alzheimer’s disease only over a small collection of pre-
selected reference genes available within a commercially
available kit.
We have recently carried out an extensive and unique
analysis of genome-wide changes of gene expression in
human brain tissue from Alzheimer’s disease (AD),
amyotrophic lateral sclerosis (ALS), Huntington’s disease
(HD), multiple sclerosis (MS), Parkinson’s disease (PD),
schizophrenia (SZ) and their respective region-speciﬁc
controls using the Illumina whole genome HumanRef8 v2
BeadChip (GEO accession number GSE26927). A total of
117 tissue samples were investigated representing various
brain regions including the spinal cord. Since RNA sam-
ples were available, we were able to validate with RT-
qPCR expression levels of candidate reference genes
extracted from the microarray data. Herein, we report a
validation exercise by identifying the most suitable refer-
ence genes that can be used as internal controls for
RT-qPCR studies in human CNS post-mortem tissue.
Materials and methods
Tissue samples
Gene expression levels from a total of 117 samples (111
different cases with 6 replicates) were included in this study
covering six neurological conditions and six different brain
areas with their respective controls (Table 1). Basic clinical
and demographic details can be found in supplemental
material1.RNAsampleswerekeptat-80 C.Asubsetwas
used for the quantiﬁcation of mRNA expression by RT-
qPCR. The subset cohort for RT-qPCR included four cases
fromeachneurologicalconditionandﬁvecontrols(n = 29).
Microarray analysis and selection of reference genes
Gene expression analysis was performed on RNA extracted
(RNeasy
 tissue lipid mini kit; Qiagen Ltd, Crawley, UK)
from snap frozen tissues [19] with the Illumina whole
genome HumanRef8 v2 BeadChip (Illumina, London, UK)
as described previously [21]. RNA concentration and pur-
ity was assessed by spectrophotometry (NanoDrop
ND1000; NanoDrop Technologies, Delaware, USA). RNA
integrity was further assessed using an Agilent 2100 Bio-
analyzer and lab-on-a-chip platform technology (Agilent
Technologies UK Ltd, West Lothian, UK). Data normali-
sation was conducted using the Rosetta error models
available in the Rosetta Resolver
 system v7.0. Gene
expression data from Illumina BeadStudio version 3.0 were
loaded into the Rosetta Resolver
 Gene Expression Anal-
ysis System version 7.0 and an error model applied to each
expression intensity from each sample. The basis of this is
described in detail in Weng et al. [52], and consists of
applying an error model to each expression intensity that
provides a p value and error term of the conservative
estimate of the gene-independent propagated error as well
as the largely gene-dependent scattered error. Inter-array
normalisation was achieved by scaling probe intensities by
a scaling factor derived from the mean intensity of the
array with 10 % outlier exclusion. Expression intensities
from probes representing the same transcript were com-
bined using an error weighted average. Annotations were
up-dated with the Rosetta Resolver system.
To establish the most stable expressed genes across all
samples, coefﬁcients of variance (CV; CV = standard
deviation divided by the mean and is expressed as a per-
centage) were calculated for all genes from the normalised
log2-transformed expression data as described by de Jongue
et al. [16]. Genes were ranked thereafter based on their CV.
The maximum fold change (MFC, the ratio of the maximum
and minimum) was also taken into account. In addition,
genes showing a ceiling effect (saturated) with their
expression level were identiﬁed when the mean was higher
than the maximum minus 2 standard deviations and were
consequently not considered. The genes of unknown func-
tion were also removed. A Pubmed search (July 2012) was
carried out on a selection of candidate genes to verify their
non-involvement in any abnormal neurological condition.
Quantiﬁcation of mRNA expression by RT-qPCR
The two-step RT-qPCR was performed using the Quanti-
Tect
 reverse transcription kit, the QuantiTect
 SYBR
Table 1 Summary table of tissue samples and number of cases
(including replicates)
Disease Brain area Control Disease
Alzheimer’s disease Entorhinal cortex 07 11
Amyotrophic lateral
sclerosis
Cervical spinal cord 10 10
Huntington’s disease Ventral head of caudate
nucleus
10 09
Multiple sclerosis Superior frontal gyrus 10 10
Parkinson’s disease Substantia nigra 08 12
Schizophrenia Temporal cortex
left BA22
10 10
Total 55 62
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123Green kit and with QuantiTect
 primer assays (Qiagen) as
previously described [19]. Brieﬂy, RT-qPCR experiments
were performed using the Mx3000P
TM real-time PCR
system with software version 4.01 (Stratagene, La Jolla,
USA). The QuantiTect
 primer assays are listed in
Table 3. For each sample, reactions were set up in dupli-
cate with the following cycling protocol, 95 C for 15 min,
40 cycles with a 3-step program (94 C for 15 s, 55 C for
30 s, and 72 C for 30 s) and a ﬁnal melting curve analysis
with a ramp from 55 to 95 C. Samples with no reverse
transcriptase reaction to test for contaminating DNA and a
negative control containing no RNA template were inclu-
ded in each run. To control for variation in RNA levels due
to manipulation across samples, the same cDNA stock was
used to investigate expression levels of the 12 reference
genes and all RT-qPCR assays for a particular gene were
undertaken at the same time in a 96-well plate under
identical conditions. Different cDNA stocks were used to
assess expression levels of target gene with different
normaliser.
To determine expression stability of the reference genes,
the quantiﬁcation cycle (Cq; aka threshold cycle), which is
the PCR cycle at which an increase in reporter ﬂuorescence
from SYBR green dye can be ﬁrst detected above noise
signal, was determined for each sample. The same
threshold level was used for all experiments. Mean Cq
from duplicates generated by the software were used to
calculate the CV for each gene investigated and then, the
reference genes were ranked.
Data accession
All data are available online through Gene Expression
Omnibus (GEO accession number GSE26927).
Statistical analysis
The following software packages were used; GraphPad
Prism 5.01 (GraphPad Software Inc, La Jolla, CA, USA)
and Microsoft
 Ofﬁce Excel
 2007 (Microsoft UK Head-
quarters, Reading, UK). A parametric t test was used to
assess group difference and the Pearson correlation testfor a
relationship between two variables. To compare variance
between groups, a Barlett’s test for equal variances test
(multiple groups) and an F test (two groups) was used with
p\0.05 suggesting a signiﬁcant difference in variances
between groups. A paired non-parametric test was used to
compare gene rankings. To test whether a group of samples
came froma Gaussian distribution, a d’Agostinoand Pearson
omnibus normality test was conducted. For multiple repe-
ated measures comparison we used the Friedman test with
Dunn’s multiple comparison test. For a particular gene,
gene expression intensity data and RT-qPCR relative
quantity data were divided by the mean of the control group
and presented as a ratio. This procedure scaled mean gene
expression levels of the controls at one. The ratio of data is
presented as mean ± standard error of means.
Results
Detection of constant genes using the microarray data
All gene transcripts from the Illumina whole genome Hu-
manRef8 v2 BeadChip (20,589) were ranked according to
their coefﬁcient of variance (CV). The CV ranged from
1.11 % (least variance) to 105.78 % (most variance). The
conventional reference genes ranked as follows in the
microarray dataset: beclin-1 (rank: 361), GAPDH (408),
QARS (1,708), actin-b (4,882), b2-microglobulin (5,334),
tubulin-b (6,008), albumin (8,376), cyclophilin A (10,457)
and HPRT1 (13,249). CYC1 and EIF4A2 [39] were ranked
259 and 938, respectively. An arbitrary cut-off of\2 % for
the CV was used to select a set of the most stable genes.
From the 170 genes selected, saturated genes and genes of
unknown functions were removed, leaving a total of 131
genes, which can be found in supplementary material 2. We
conducted a thorough search using PubMed on the genes at
the top of the list to retain only those with no known reports
(at the time of the search) of abnormal expression in any
CNS disorder until we isolated a number of potential can-
didates. A total of eight candidate reference genes of
various functions were retained. Post-mortem delay (PMD)
and age at death were taken into consideration since reports
suggest that these variables may impact on the expression of
certain mRNA species despite extreme care given to con-
vert the same amount of mRNA from all samples [19]. RIN
was not considered since the samples in the present study
were pre-selected for their ‘‘good’’ and homogeneous RNA
quality, which is one of the prerequisites for conducting a
microarray experiment. Consequently, they do not represent
the full range of tissue quality available within tissue banks
as tests showed that RIN values did not come from a
Gaussian distribution, unlike PMD (p = 0.0123) and age at
death (p = 0.0097). Despite small gene expression vari-
ances, signiﬁcant shifts in expression due to disease were
detected for some genes, which we believe may account for
our results, especially for GAPVD1 and BECN1 (see later
section; Table 2). Finally, variations in expression between
brain regions, groups and disease type (Barlett’s tests for
equal variances and F test) were considered. One of the
homogeneity of variance violations found for the 12 genes
as listed in Table 2 was for GAPDH showing a more stable
expression in the superior frontal gyrus grey matter com-
pared to other brain regions (Fig. 1 and supplemental
material 3a). No consistent variance in expression between
896 Acta Neuropathol (2012) 124:893–903
123control and disease group across disease states were
observed for those 12 genes (supplemental material 3b) and
no signiﬁcant changes were observed across diseases
(supplemental material 3c).
Comparison of expression between two hybridisation
techniques
Expression stability of the eight novel reference genes, in
addition to four more commonly used reference genes
(GAPDH, BECN1, QARS and TUBB), was veriﬁed using
RT-qPCR on a subset cohort (n = 29) from the microarray
study. We ﬁrst veriﬁed that selecting a smaller subset
cohort of the microarray dataset did not signiﬁcantly affect
the ranking of the selected genes. We compared ranking
based on CV. Only minor signal expression variations in
ranking were detected between the entire and the subset
cohort but were not found to be signiﬁcantly different
(Wilcoxon signed rank test). The four common reference
genes that showed the least expression stability over 117
samples remained the least stable in the smaller cohort
comprised 29 samples. Cq values from RT-qPCR experi-
ment (n = 29) were also ranked based on CV. Finally, a
ﬁnal average rank was given and all rankings can be found
in Table 3 and a summary in Table 4.
We then compared the stability in expression of those 12
genes between the two hybridisation techniques. Statisti-
cally, there was no difference between all 3 ranking orders
of those 12 genes nor was any statistical difference in
ranking found between the two hybridisation techniques
(Wilcoxon matched pairs test). However, some changes in
ranking order were noticed. The most striking disparity in
expression between the two techniques was for BECN1 and
ATP5E. Expression levels for BECN1 with RT-qPCR were
very stable and placed BECN1 at position 1 compared to
the microarray data, while ATP5E moved from position 2
in the microarray data to position 12 with RT-qPCR. In
summary, the novel investigated genes XPNPEP1, OBSP
and AARS showed an overall better or comparable
expression stability than the commonly used reference
genes.
Performance as normalisers of novel reference genes
Since, RT-qPCR represents the gold standard to validate
gene expression changes from cDNA microarrays, we
assessed the eight top reference genes from the overall
ranking (XPNPEP1, AARS, GAPVD1, ATP5E, OSBP,
CSNK2B, BECN1 and QARS; in ranking order; see
Table 4) as normalisers for a GOI to determine whether
they were able to replicate the increased microarray
expression levels of the GOI. Transforming growth factor,
beta receptor II (TGFBR2) was chosen as the test-gene of
interest. This gene was up-regulated in Huntington’s dis-
ease by 1.74-fold by microarray analysis. Except for
GAPVD1 and QARS, all normalisers were able to repro-
duce signiﬁcantly increased levels of TGFBR2 in HD from
the microarray, albeit with a different magnitude of change
Table 2 Correlation with post-mortem delay and age at death and group comparison (control vs. disease)
ATP5E AARS GAPVD1 CSNK2B XPNPEP1 OSBP NAT5 DCTN2 BECN1 GAPDH QARS TUBB
Post-mortem delay (Pearson r)
r 0.142 -0.129 0.072 -0.024 -0.060 0.000 0.014 -0.072 -0.013 0.064 0.119 -0.110
p 0.132 0.174 0.449 0.798 0.528 1.000 0.883 0.451 0.887 0.498 0.208 0.247
Age at death (Pearson r)
r 0.119 -0.182 0.153 -0.171 -0.124 -0.111 -0.149 -0.067 -0.114 0.132 0.189 -0.233
p 0.201 0.051 0.101 0.065 0.183 0.235 0.110 0.474 0.222 0.156 0.042 0.012
Disease (t test)
0.029 0.208 0.000 0.042 0.863 0.377 0.102 0.083 0.009 0.122 0.662 0.024
Signiﬁcant results are in bold/italic
Fig. 1 Expression variation across brain regions for GAPDH. The
Barlett’s test for equal variances was signiﬁcant for GAPDH
(p = 0.0022) meaning that there was a signiﬁcant effect in expression
variability across brain regions (control ? disease samples). More
precisely, GAPDH expression was more stable in the superior frontal
gyrus grey matter (grey matter lesions from MS patients) than any
other brain region (refer to Table 1 for the full brain region listing)
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123(Fig. 2a). A good correlation in expression levels between
the microarray and the RT-qPCR data was found with the
exception of GAPVD1 (Table 5). From the novel reference
genes, XPNPEP1, AARS, OSBP and CSNK2B replicated
most efﬁciently the fold change of the test-gene of interest.
TGFRB2 expression in HD was 1.0-fold higher with
BECN1 (mean = 3.22 ± 1.07) and reduced with ATPE5
(mean = 1.6 ± 2.03) as normalisers. The higher expres-
sion of TGFRB2 when using BECN1 as normaliser could
be explained due to signiﬁcant variances of mRNA BECN1
levels in the disease group compared to controls, similarly
for GAPDV1 (Fig. 3). XPNPEP1 and AARS were retained
as will be discussed thereafter. In addition, using another
GOI, TNFRSF14 (tumour necrosis factor receptor super-
family, member 14), which was signiﬁcantly up-regulated
(microarray data: 91.94; p\0.001) in PD [21], expression
levels were compared using BECN1 and XPNPEP1 as
normalisers (Fig. 2b). The signiﬁcantly increased expres-
sion levels of TNFRSF14 were more closely matched to
the expression levels from the microarray output when
XPNPEP1 was used as normaliser (92.04; p\0.01)
compared to BECN1 (91.61; p\0.05).
Validation using independent datasets
In the ﬁrst instance, we used two additional microarray
datasets, available from our laboratory, to consolidate that
XPNPEP1 is stably expressed across samples and com-
pared its expression to more commonly references genes
Table 3 Ranking of candidate novel reference genes and four commonly used reference genes (in bold) based on microarray and RT-PCR data
Name Description Entrez
gene
Accession
code
Catalogue
number
(Qiagen)
Microarray
ranking
a
(n = 117)
Microarray
ranking
(n = 29)
RT-PCR
ranking
(Cq)
Overall
rank
(avg)
Novel candidate reference genes
ATP5E ATP synthase, H ? transporting,
mitochondrial F1 complex,
epsilon subunit, nuclear gene
encoding mitochondrial protein
514 NM_006886.2 QT00096852 7 (1) 2 12 4
AARS Alanyl-tRNA synthetase 16 NM_001605.1 QT00054747 17 (2) 3 6 2
GAPVD1 GTPase activating protein and
VPS9 domains 1
26130 NM_015635.2 QT00083440 28 (3) 4 7 3
CSNK2B Casein kinase 2, beta polypeptide 1460 NM_001320.5 QT00012446 70 (4) 5 10 6
XPNPEP1 X-prolyl aminopeptidase
(aminopeptidase P) 1, soluble
7511 NM_020383.2 QT00051471 73 (5) 1 3 1
OSBP Oxysterol binding protein 5007 NM_002556.2 QT00072219 76 (6) 6 4 5
NAT5 N-acetyltransferase 5 (ARD1
homolog, S. cerevisiae),
transcript variant 3
51126 NM_181528.1 QT00057407 85 (7) 7 11 10
DCTN2 Dynactin 2 (p50) 10540 NM_006400.3 QT01014895 131 (8) 8 9 9
Common
BECN1 Beclin 1 (coiled-coil, myosin-like
BCL2 interacting protein)
2597 NM_002046.2 QT00004221 361 (9) 10 1 7
GAPDH Glyceraldehyde-3-phosphate
dehydrogenase
5859 NM_005051.1 QT01192646 408 (10) 9 8 11
QARS Glutaminyl-tRNA synthetase 5859 NM_005051.1 QT00203455 1708 (11) 11 2 8
TUBB Tubulin, beta 203068 NM_178014.2 QT00089775 6008 (12) 12 5 12
a Those genes were relabelled 1–12 (in brackets) according to their position in the whole genome microarray dataset
Table 4 Summary ranking table
Rank Microarray
(n = 117)
Microarray
(n = 29)
RTPCR Cq
(CV)
Overall
1 ATP5E XPNPEP1 BECN1 XPNPEP1
2 AARS ATP5E QARS AARS
3 GAPVD1 AARS XPNPEP1 GAPVD1
4 CSNK2B GAPVD1 OSBP ATP5E
5 XPNPEP1 CSNK2B TUBB OSBP
6 OSBP OSBP AARS CSNK2B
7 NAT5 NAT5 GAPVD1 BECN1
8 DCTN2 DCTN2 GADPH QARS
9 BECN1 GAPDH DCTN2 DCTN2
10 GAPDH BECN1 CSNK2B NAT5
11 QARS QARS NAT5 GAPDH
12 TUBB TUBB ATP5E TUBB
Commonly used reference genes are in bold
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123such as BECN1 and GAPDH. XPNPEP1 showed less
variance in expression across samples in both datasets (see
Table 6). Also, using a different RT-qPCR protocol and
different samples, we found that XPNPEP1 expression was
more stable measured by qPCR on Cq values (CV = 7.22;
mean = 27.30; SD = 1.974) than GAPDH (CV = 10.60;
mean = 21.85; SD = 2.317) in tissue from 10 control
white matter samples and 12 MS white matter lesions [20].
We also used an external microarray dataset (GSE13162)
from human tissue (frontotemporal cortex) samples (Af-
fymetrix Human Genome U133A 2.0 Array) available
from Gene Expression Omnibus (GEO) [13]. The CV of
individual probes for XPNPEP1, ACTB, BECN1, GAPDH
and HPRT1 show that XPNPEP1 expression was more
stable than BECN1 but not GAPDH or ACTB (Table 7).
Finally, we investigated further whether the use of
XPNPEP1 as a novel reference gene could also be applied
to RT-qPCR mouse brain studies. From a listing available
at the Allen Institute for Brain Science, we selected three
mouse microarray datasets. The ﬁrst dataset (GSE16496)
was published by Kasukawa et al. [29] and used the Af-
fymetrix platform (Affymetrix Mouse Genome 430 2.0
Array). The second study (GSE26024) used the Illumina
MouseRef-8 v2.0 BeadChip on 21 samples [5] and the third
(GSE9566) used again the Affymetrix platform as men-
tioned above, but, instead of whole tissue samples, gene
expression changes in isolated CNS cells, i.e., neurones,
astrocytes and oligodendrocytes were compared [11]. A
summary of the results can be found in Table 8. Xpnpep1
was well within the lower CV range amongst the selected
common reference genes, Actb, Becn1, Gapdh and Hprt
(see supplementary material 4 for individual data), which
placed Xpnpep1 as an equal or better reference gene than
some common ones currently in use for RT-qPCR studies
for human, mouse and single cell CNS samples.
Discussion
The pathogenetic mechanisms underlying the major neu-
rodegenerative disorders are still poorly understood. Our
recent microarray gene expression studies aimed to look
for common pathways of degeneration underlying disease.
In doing so, we wanted to overcome some of the short-
comings previously encountered when using microarray
technology, such as the use of different microarray plat-
forms, different analytical software tools or inadequate
normalisation. By studying expression data from six dif-
ferent neurological conditions together with their
respective controls, we have been able to generate a list of
the most stably expressed genes within the CNS not
affected by on-going disease processes that can now be
used as reference genes. We propose herein XPNPEP1 as a
Fig. 2 qPCR data for TGFBR2
(a) and TNFRSF14 (b) using
different normalisers. The black
dotted lines represent the
expression levels of controls. In
the ﬁrst panel a, except for
GAPVD1 and QARS, all
normalisers were able to
replicate signiﬁcantly
(p\0.05) increased levels of
TGFBR2 in disease (91.74—
microarray data). In b,
XPNPEP1 (92.04; p\0.01) as
normaliser produces a closer
match to microarray output
(microarray data 91.94;
p\0.001) than BECN1
(91.61; p\0.05). **p\0.01
and *p\0.05
Table 5 Correlations between the PCR expression data of a GOI,
TGFBR2 (91.74), using different normaliser and the microarray data
Reference gene FC
PCR
XY
pairs
Pearson
r
R
squared
P value
TGFRB2/
XPNPEP1
2.34 16 0.7873 0.6199 0.0003
TGFRB2/AARS 2.31 16 0.8116 0.6587 0.0001
TGFRB2/
GAPVD1
1.16 16 0.5606 0.3143 0.0239
TGFRB2/ATP5A 1.60 16 0.8696 0.7562 \0.0001
TGFRB2/OSBP 1.82 16 0.8406 0.7066 \0.0001
TGFRB2/
CSNK2B
1.80 16 0.8389 0.7037 \0.0001
TGFRB2/BECN1 3.22 16 0.7773 0.6042 0.0004
TGFRB2/QARS 2.09 16 0.8526 0.7269 \0.0001
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123more suitable reference gene for the purpose of normali-
sation for CNS gene expression studies using post-mortem
tissues and also offer a list of potential alternatives.
The expression of the XPNPEP1 [X-prolyl aminopep-
tidase (aminopeptidase P) 1, soluble] gene showed
excellent stability in our analysis. XPNPEP1 is localised on
Fig. 3 Expression levels of XPNPEP1 (a), GAPVD1 (b) and
BECN1 (c). Despite a smaller coefﬁcient of variance of expression for
GAPVD1 (b;C V= 1.56) than XPNPEP1 (a;C V= 1.76) across our
samples (control = 55 and disease = 62), there was a signiﬁcant shift
toward an increased expression in the disease group not observed with
XPNPEP1 where expression was homogeneous irrespective of disease
state. A signiﬁcant shift towards a decrease in expression was found
for BECN1 (c). ***p\0.001 and **p\0.01
Table 6 Coefﬁcient of variance comparison between XPNPEP1, BECN1 and GAPDH in two additional microarray datasets of human grey
matter tissue from several brain regions
Dataset 1 Dataset 2
Platform HumanRef-8 V3 HumanRef-8 V3
Normalisation protocol Beadstudio (quantile) Resolver Rosetta
Log2 transformation Yes Yes
Total samples including replicates 79 50
Cohort Area Cond Cont Dis Area Cond Cont Dis
Dorsal caudate HD 10 10 SFG MS 10 40
Putamen HD 10 10
ACC SZ 09 09
SFG CJD 10 11
Results CV Mean SD CV Mean SD
XPNPEP1 2.165 9.567 0.207 1.669 9.463 0.158
GAPDH 2.227 11.960 0.266 1.677 12.227 0.205
BECN1 3.374 7.751 0.262 4.731 7.953 0.376
Cond condition, Cont control, Dis disease, ACC anterior cingulate cortex, CJD Creutzfeldt-Jakob disease
Table 7 Coefﬁcient of variance of XPNPEP1 in human microarray dataset (GSE13162) [12]
XPNPEP1 ACTB BECN1 GAPDH HPRT1
Probe CV Probe CV Probe CV Probe CV Probe CV
209045_at 2.677 213867_x_at 1.763 208945_s_at 3.172 212581_x_at 2.571 202854_at 13.450
222072_at 4.373 200801_x_at 1.854 208946_s_at 5.452 213453_x_at 2.626
208453_s_at 5.695 217398_x_at 2.695
217380_s_at 7.047
Bold values indicate the probe with the smallest CV for each gene
n = 56
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123chromosome 10q25.3 and can be found in a wide variety of
organisms including mammals, yeasts, and bacteria and a
variety of tissues including lung, kidney, brain, adrenal
medulla and cell types such platelets, lymphocytes, and
astrocytes [36]. Northern blot analysis indicates that this
gene product is ubiquitously expressed [50]. It shows
amino acid homology with Escherichia coli methionine
aminopeptidase, a prototypical member of the ‘‘pita bread-
fold’’ family [4]. This novel class of proteases remove the
N-terminal methionine from proteins and peptides, a cru-
cial step in the maturation of many proteins towards
initiating biological activity, adequate subcellular locali-
sation and eventual degradation [37, 38]. The human
XPNPEP1 consists of 623 amino acid residues with a
calculated molecular mass of 69,886 Da, and has been
shown to hydrolyse bradykinin—a small vasoactive pep-
tide involved in a variety of biological processes [36]. Our
ﬁndings suggest that increased expression levels of a GOI
were better replicated with XPNPEP1 as normaliser than
with BECN1. Beclin-1 plays a central role in autophagy
[28] and has recently been shown to increase in expression
in neurones at the site of traumatic brain injury [12]. Also,
neurodegeneration was shown to induce up-regulation of
beclin-1 [23]. In the mammalian adult brain beclin-1 is
expressed in neurones and astrocytes, and up-regulation of
beclin-1 has been reported in injured neurones [53] and in a
subpopulation of astrocytes reacting to injured neuronal
components [18]. Absolute mRNA expression of beclin-1
will be therefore subject to variances depending on total
neuronal cell numbers and disease activity. Thus, caution is
required in the use of this reference gene in the study of
neurodegeneration.
AARS (alanyl-tRNA synthetase) belongs to a family of
20 cellular enzymes, the aminoacyl-tRNA synthetases,
responsible for translating nucleotide triplets in genes and
mRNAs. These enzymes are involved in a number of
functions such as translational ﬁdelity, tRNA processing,
RNA splicing, RNA trafﬁcking, apoptosis and transcrip-
tional and translational regulation [41, 47]. No changes in
expression of alanyl-tRNA synthetase (AlaRS) have been
associated with any neurodegenerative disorders; however,
mutation in the AlaRS protein was shown to lead to Pur-
kinje cell degeneration in rodents [34], to peripheral axonal
degeneration and cause autosomal dominant Charcot-
Marie-Tooth disease [45]. Our preliminary evidence would
suggest that AARS was more invariant than QARS (a
common reference gene). We have investigated only one
member (AARS) of this group of genes. However, other
members may also be good candidates. OSBP (Oxysterol
binding protein) is thought to act as a sensor of sterols [24]
and overexpression of OSBP has been linked to increased
cholesterol and sphingomyelin levels [32]. Although there
is no known involvement of OSBP in any CNS disorders as
yet, cholesterol metabolism alterations have nevertheless
been shown to play a role in the pathophysiology of mul-
tiple CNS disorders [1, 30] and therefore would not be an
ideal reference gene. Finally, the CSNK2B (Casein kinase
2, beta polypeptide) gene is located on chromosome 6p21,
the human major histocompatibility complex [2]. Although
not associated with any diseases as yet, it is well estab-
lished that the human major histocompatibility complex is
associated with many autoimmune/inﬂammatory diseases,
and therefore was not retained.
In conclusion, the generation of expression proﬁles for
several neurological disorders, representing various CNS
regions allowed us to provide a selection of candidate
invariant genes with potential to be useful as novel refer-
ence genes for appropriate normalisation of qPCR data
from human CNS post-mortem tissue studies. By doing so,
we overcame some of the shortcomings encountered with
microarray studies. We isolated an initial 131 genes from
the microarray data using the coefﬁcient of variance over
other methods available [49] and veriﬁed expression levels
from a selection of genes in a sub-cohort of the microarray
study using RT-qPCR. We were able to test several can-
didate genes as normalisers for a target GOI. XPNPEP1
and AARS performed best in replicating gene expression
levels from the microarray data using RT-qPCR. XPN-
PEP1 performed better than BECN1 in being able to
replicate microarray data. This impetus in the search for an
appropriate reference gene has emerged due to rising
concerns about the validity of the commonly used refer-
ence genes [8, 9, 33] and the importance of following
stringent standards for molecular expression studies [10].
Although it is advisable to test for the most appropriate
reference gene in each experimental setting and to use
multiple reference genes, it is nevertheless very useful to
have one established reliable tissue-speciﬁc reference gene,
Table 8 Coefﬁcient of variance of XPNPEP1 in mouse microarray datasets (summary)
Dataset Reference Platform n Xpnpep1 CV Min CV Mean
a CV Max CV
GSE16496 Kasukawa et al. [29] Affymetrix Mouse Genome 430 2.0 Array 102 2.635 1.014 2.650 5.480
GSE26024 Bottomly et al. [5] Illumina MouseRef-8 v2.0 24 1.446 0.945 2.265 5.690
GSE9566 Cahoy et al. [11] Affymetrix Mouse Genome 430 2.0 Array 38 2.449 1.480 5.188 12.174
a Probes for Actb, Becn1, Gapdh and Hprt (see supplemental material 4 for all data)
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123in particular, for single target gene expression investiga-
tions using RT-qPCR in a particular CNS disease. We
provide herein one validated novel reference gene, XPN-
PEP1, useful for RT-qPCR studies of the human CNS and a
list of other potential candidates.
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